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Abstract: Mouse embryonic stem (ES) cells are defined
by their capacity to self-renew and their ability to
differentiate into all adult tissues including the germ line.
Along with efficient clonal propagation, these properties
have made them an unparalleled tool for manipulation of
the mouse genome. Traditionally, mouse ES (mES) cells
have been isolated and cultured in complex, poorly
defined conditions that only permit efficient derivation
from the 129 mouse strain; genuine ES cells have not
been isolated from another species in these conditions.
Recently, use of small molecule inhibitors of glycogen
synthase kinase 3 (Gsk3) and the Fgf-MAPK signaling
cascade has permitted efficient derivation of ES cells from
all tested mouse strains. Subsequently, the first verified ES
cells were established from a non-mouse species, Rattus
norvegicus. Here, we summarize the advances in our
understanding of the signaling pathways regulating mES
cell self-renewal that led to the first derivation of rat ES
cells and highlight the new opportunities presented for
transgenic modeling on diverse genetic backgrounds. We
also comment on the implications of this work for our
understanding of pluripotent stem cells across mamma-
lian species.
Introduction
Embryonic stem (ES) cells were first isolated in 1981 by Martin
in California [1] and Evans and Kaufman in Cambridge [2].
These cells derive from the transient epiblast compartment of the
pre-implantation mouse blastocyst that would go on to form the
embryo proper in vivo [3]. In vitro, ES cells can self-renew
indefinitely without genetic transformation, can be expanded
clonally, and retain pluripotency, which is the ability to
differentiate into all adult cell types, including the germ cells [4].
The development of homologous recombination technology in
cultured mammalian cells and its application to mouse ES (mES)
cells made possible extensive targeted manipulation of the mouse
genome; the engineered cell lines and the mice derived from them
have revolutionized our ability to study the effects of gene function
in mammalian biology and disease [5]. In 2007, the importance of
these technological advances was recognized by the Nobel
Committee, who awarded the Prize in Physiology or Medicine
to Evans, Capecchi, and Smithies [6].
Hopes that other animals would yield ES cells, facilitating
genetic manipulation in diverse species, met with frustration [7].
While cell lines could be established from early embryos of other
species, they were not pluripotent. Even in the mouse, only the 129
strain from which ES cells were originally isolated proved
consistently amenable to ES cell derivation and genetic manipu-
lation. However, this strain has the disadvantage of poor breeding
efficiency and is seldom the model of choice; multiple costly and
time-consuming generations of backcrossing are required to
transfer a genetic manipulation from a 129 transgenic to a desired
genetic background.
In the late 1990s, pluripotent cell lines were derived from non-
human primate and human blastocysts and deemed to be ES cells
[8–10]. However, they were found to rely upon distinct signaling
pathways to be maintained [11]. More recently, human ES (hES)
culture conditions were used to isolate cell lines from the post-
implantation mouse epiblast; these were named epiblast stem cells
(EpiSCs) [12,13]. Primate ES cells and mouse EpiSCs are distinct
from mES cells and they share several features that hinder their
use with genetic technologies including resistance to single cell
dissociation [12–14], reduced karyotype stability [15,16], and
limited capacity for chimera formation and germline contribution
[12,13,17].
EpiSCs and mES cells are considered to represent the
developmental stages from which they are derived: the post- and
the pre-implantation epiblast, respectively (Figure 1) [18]. By the
post-implantation stage, random X-inactivation has occurred in
the epiblast cells and they are poised to respond to inductive cues
at the onset of gastrulation. Likewise, female EpiSCs also harbor
an inactive X [19] and may be ‘‘primed’’ towards differentiation as
indicated by increased expression of lineage-specific markers
[12,13]. In contrast, in the earlier pre-implantation blastocyst, cells
of the epiblast have just been epigenetically ‘‘reset.’’ This is
indicated by the reactivation of the paternal X chromosome
exclusively in the epiblast cells (of female embryos) [20,21]. This
more ‘‘naı ¨ve’’ state appears to be preserved in ES cells, which also
harbor two active X chromosomes (when female) and are
considered to have an open chromatin conformation [22].
Our limited ability to capture naı ¨ve pluripotent stem cells has
been a barrier to efficient genetic manipulation in non 129-strain
mice and other species. ES cells also have been widely used as a
model to study early development and lineage commitment
(reviewed in [23]). However, the hitherto limited applicability of
ES cell principles across species challenged the relevance of this
research to mammalian development in general.
Recently, it has been demonstrated that mES cells can be
derived and maintained using small molecule inhibitors of Gsk3
and the Fgf-MAPK signaling cascade (CHIRON99021 and
PD0325901, respectively) [24]. This two-inhibitor (2i) culture
condition has facilitated the derivation of ES cells from all tested
mouse strains [24,25] and several strains of a second species, Rattus
norvegicus [26–29]. The demonstration that genuine naı ¨ve ES cells
can be derived from the rat in the same culture conditions suggests
Citation: Blair K, Wray J, Smith A (2011) The Liberation of Embryonic Stem
Cells. PLoS Genet 7(4): e1002019. doi:10.1371/journal.pgen.1002019
Editor: David R. Beier, Harvard Medical School, United States of America
Published April 7, 2011
Copyright:  2011 Blair et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: The authors received no specific funding for this article.
Competing Interests: The authors have declared that no competing interests
exist.
* E-mail: ags39@cam.ac.uk
PLoS Genetics | www.plosgenetics.org 1 April 2011 | Volume 7 | Issue 4 | e1002019that mES cells may indeed represent a common developmental
stage, at least in rodents. It has also been reported that hES cell
lines can be ‘‘reprogrammed’’ to a state similar to naı ¨ve
pluripotent mES cells [30], suggesting that this state is more
widely conserved across mammals.
Defining the Requirements for Self-Renewal
Classical culture conditions employed serum-containing media
and a layer of mitotically inactivated fibroblasts (feeder) cells [1–3].
Initially, little was known about the molecular nature of the self-
renewal signals provided by these components. However, in 1988,
the key contribution of feeders was determined to be the IL-6
family cytokine LIF [31,32]. More recently, the anti-neural
cytokine BMP4 was found to substitute for serum, and by
combining BMP and LIF a defined, feeder-free, serum-free culture
condition for ES cell derivation and maintenance was created
[33].
The apparent dependence of ES cells upon growth factors
underpinned a belief that exogenous signals drive ES cell
maintenance. Downstream of LIF, Stat3 was identified as a
major functional mediator of self-renewal [34,35]. The MAPK/
Erk pathway was also suspected to be a self-renewal pathway due
to its placement downstream of LIF and relatively high
activation in ES cells, but was paradoxically found to promote
ES cell differentiation [36]. More recently, it has been
demonstrated that in serum-free conditions MAPK/Erk activity
is driven primarily by autocrine Fgf4 signaling [37]. Importantly,
genetic or pharmacological inhibition of the Fgf-MAPK pathway
blocks efficient ES cell differentiation [36–39]. This finding
indicates that shielding ES cells from the inductive signals in
their environment is an important aspect for their maintenance
in vitro. It has also been observed that early embryos defective in
MAPK/Erk signaling [40] or exposed to Mek1/2 [41] or Fgfr
[42] inhibitors form an expanded epiblast at the expense of
extra-embryonic endoderm, suggesting that the in vitro sensitiv-
ity of ES cells to Fgf-MAPK signaling reflects a mechanism of
early cell fate decision in vivo. However, Fgf-MAPK pathway
inhibition alone is not sufficient for clonal propagation of mES
cells. Inhibition of Gsk3 (independently shown to enhance ES
cell propagation by pharmacological [43] and genetic [44]
means) in addition to Fgf-MAPK restores clonogenicity and
permits de novo derivation and long-term propagation of mES
cells. Inhibition of Gsk3 up-regulates a broad range of metabolic
and biosynthetic processes (reviewed in [45]), and in ES cells,
leads to the alleviation of Tcf3-mediated repression of pluripo-
tency factors (J. Wray, T. Kalkan, S. Gomez-Lopez, D. Eckardt,
A. Cook, et al, unpublished data). Stat3-null ES cells can be
derived using Gsk3 and Fgf-MAPK pathway inhibitors (2i),
formally proving that extrinsic LIF-STAT3 signaling is not
necessary for ES cell self-renewal in these conditions [24].
However, wild-type mES cells cultured in 2i remain sensitive to
LIF, exhibiting enhanced cloning efficiency in 2i+LIF as
compared to 2i alone [24]. This optimized condition, 2i+LIF,
Figure 1. The origin and properties of naı ¨ve and primed pluriopotent stem cells.
doi:10.1371/journal.pgen.1002019.g001
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recalcitrant strains and species.
Overcoming Recalcitrance
In 1997, Brook and Gardner noted a ‘‘persisting ignorance
about the genetic basis of permissivity’’ [3]. The ‘‘permissivity’’
they referred to was the particular propensity of the 129 strain of
mouse for ES cell derivation. The 129 strain was fortuitously used
in the first derivations of ES cells due to the historical progression
that led from studies of germ line carcinomas to this work [46].
Using conventional serum and feeder conditions, 10%–30%
derivation efficiency can be routinely achieved from 129
blastocysts [47,48]. Brook and Gardner even reported 100%
efficiency [3] by deriving from microsurgically isolated epiblasts of
implantation-delayed 129 embryos.
While the susceptibility of the 129 strain to ES cell derivation
may be related to its propensity to develop gonadal teratomas
(tumors with cell types of all three germ layers) [49], the basis of
non-129 strain recalcitrance is not fully understood. Strain
variation in derivation efficiency and in vitro colony formation
appear to correlate with differential Fgf-MAPK signaling [50,51],
but the underlying mechanisms have not been elucidated. Using
techniques such as implantation delay, micro-dissection, and
inhibitors of Mek1/2 in combination with serum and feeders, ES
cell derivation was reported from C57BL/6 [52], DBA/1lacJ [53],
CD1 [54], C57BL/6 X CBA [55], PO [3], and CBA and CBA/
Ca [3,50,56], but efficiencies remained low. Only certain serum
batches are suitable for ES cell culture, and the use of serum may
have hindered derivation from recalcitrant strains. The develop-
ment of serum-free media [33] has eliminated this variable and
provided a platform for further optimization of ES cell culture and
derivation.
Indeed, serum-free 2i culture condition has overcome the
limitations imposed by mouse genetic background on ES cell
derivation and maintenance. In striking contrast to conventional
culture, 2i+LIF yields stable ES cell lines from any tested strain of
mouse with high efficiency [24,25]. Germline-competent ES cell
lines have been established not only from 129 mice, but also CBA
and MF1 [24] as well as NOD [25] and FVB (J. Nichols, E.
Michalak, J. Jonkers, unpublished data). Gene targeting in strains
with biologically divergent genetic make-ups and phenotypes is
now achievable. Moreover, these culture conditions open up the
possibility of generating ES cells from existing transgenics,
facilitating efficient combination of targeted mutations.
Conquering Rodentia
Soon after the first mES cells were derived, work began to
isolate ES cells from the rat [57]. As a closely related species and
fellow rodent, it seemed a reasonable choice. Furthermore, as the
rat is extensively used to study physiology, cognition, and
behavior, access to the germline for precise genetic manipulation
would be an invaluable tool. However, for 27 years, all attempts
were met with failure. Multiple groups, including ours, had
reported the derivation of cell lines from rat blastocysts [58–62].
But the identity of these lines range from contaminating mES cells
[57,61] to cell lines with properties of extra-embryonic lineages
[58,60–63]; none have proved capable of colonizing the germline
of chimeras.
However, utilizing 2i, LIF, and fibroblast feeder cells, cells with
the morphology and gene expression pattern of ES cells, and most
importantly, the ability to contribute to chimeras and make
functional germ cells, were derived from the SD [26] and DA [27]
strains of rat. This result confirms that a naı ¨ve pluripotent cell type
can be captured in a species other than the mouse. Other groups
have since validated rat ES cell derivation using the two inhibitors
to isolate germline-competent cells from several wild-type and
transgenic strains [64,65]. As of yet, no variability in derivation
efficiency among strains has been noted, suggesting that ES cells
may become available from a multitude of disease modeling rat
strains such as the SHR. Notably, both lines reported by
Hirabayashi et al. were female [29], as were all six lines derived
by Kawamata and Ochiya [28] and all but one line reported by
our group [26]. A recent isolation of pluripotent embryonic germ
(EG) cells derived from rat primordial germ cells also reported
exclusively female lines [66]. While it is apparent that both male
and female isolated epiblasts form outgrowths at near 100%
efficiency, male lines proliferate more slowly during early passages
(K. Blair, unpublished data) and may therefore be selected against
early during the derivation process. The underlying cause of this
bias against male cells remains unknown, but overcoming it will be
important for efficient germline modification.
Qi-Long Ying’s group recently reported successful targeting of
the p53 locus in rat ES cell by homologous recombination [67].
This proof of principle report represents a long-awaited advance in
the field of rat genetics [68] and mammalian transgenesis, given
that the rat is perhaps the most widely used mammalian model
with an extensively characterized physiology and behavior [69].
However, this report also highlighted a key difference between
mouse and rat ES cells and a potential limitation of rat ES cells as
a tool to access the rat germline. While genetic integrity is a
hallmark of the mES cell, karyotype stability is a recurrent
problem with rat ES cells [26,27,70]. Both initial reports indicated
karyotypic instability in higher passage cells [26,27] and initial
attempts to transmit the p53 knockout through the germline failed,
with the authors citing .65% polyploidy of the injected line as a
likely cause. Only through sub-cloning and careful morphological
selection during passaging was a karyotypically normal, germline-
competent line maintained [70].
For the full potential of rat ES cells for genetic research to be
realized, cell lines and culture methods should be further
optimized. It should be remembered that before optimization
and standardization of culture conditions throughout the mES cell
field, it was widely considered that only early passage cells were
germline competent and useful for gene targeting [7], whereas we
now know that in the right conditions, mES cells are stable for
many generations. Work has begun to optimize rat ES cell culture
for stability. Kawamata and Ochiya have reported high germline
competence on feeders with their culture media, YPAC [28], a
serum-based media with 2i inhibitors, as well as a ROCK inhibitor
(shown to reduce dissociation associated apoptosis in hES cells
[14]) and an Alk inhibitor (suggested to suppress differentiation of
putative rat induced pluripotent stem (iPS) cells [71]). They
achieved germline competence from 3/3 lines tested. These results
are encouraging, but ideal conditions for culturing ES cells will be
those that are highly reproducible among laboratories. Therefore,
it is desirable to eliminate undefined, variable components such as
serum and feeders. Optimized conditions for the culture of rat ES
cells may in turn help us to unlock the naı ¨ve pluripotent state in
other species, including the human.
Towards Naı ¨ve Human ES Cells
Human and non-human primate ES cells were originally
derived by Thomson and colleagues from pre-implantation
blastocysts using serum and feeders [8–10]. However, despite the
similarity of these conditions to those conventionally used to
culture mES cells, it has now become clear that these cells have
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sustain mES cells, Fgf2 and Activin have been identified as the
signals that support the maintenance of hES cells [11]. This
distinction was initially attributed to species differences. However,
more recently, Fgf2/Activin-dependent cell lines were isolated
from post-implantation mouse epiblasts [12,13]. These cell lines
were termed epiblast stem cells (EpiSCs) to distinguish them from
ES cells. They were also reported to be derived from the rat,
though these cells exhibit different Fgf-responsiveness [13]. EpiSCs
cannot be derived or maintained in 2i. Furthermore, while ES cells
contribute to chimeras with high efficiency, only a small sub-
population of EpiSCs under certain culture conditions has this
capacity [17]. hES cells are more similar to EpiSCs than they are
to mES cells with respect to global gene expression and behavioral
characteristics [12,13], suggesting that hES cells advance devel-
opmentally during derivation and that the culture conditions
employed tend to capture an EpiSC-like state. However, hES are
not identical to mouse EpiSC, expression differences in certain key
genes have been identified [72], and the X-inactivation status of
female hES seems variable [73,74]. These differences may be
attributable to species divergence in epiblast development [75].
As previously noted, the primed, EpiSC-like state of hES cells is
accompanied by characteristics such as low viability after single
cell dissociation [12–14] and reduced karyotype stability [15,16]
that make them inefficient, though usable, for genetic technology
applications [76]. Also, the different developmental states
represented by mouse and hES cells dictate that the many
established in vitro differentiation protocols developed in the
mouse do not translate well to the human system. The derivation
of hES cells with characteristics of naı ¨ve ES cells would facilitate
the transfer of knowledge from model organism to its human
equivalent.
EpiSCs can be reprogrammed to an ES cell state by over-
expression of the pluripotency transcription factors Nanog [77],
Klf4 [19], and Klf2 [78] by Nr5a receptors [79], Stat3 activation
[80], or by rare spontaneous reprogramming events [81].
Recently, the Jaenisch group employed reprogramming tech-
niques to establish mES-like human cell lines from fibroblasts and
existing hES cells [30]. They established lines in 2i+LIF that
exhibited an epigenetic and gene expression profile similar to mES
cells. Like both mouse and rat ES cells, but unlike established hES
cells, they responded functionally to LIF. However, these naı ¨ve
hES cell lines were dependent on continued expression of the
reprogramming transgenes. The addition of forskolin to the media
allowed the establishment of naı ¨ve hES cell lines that were not
dependent on transgene expression but these lines could not be
maintained for more than 20 passages. Also using a reprogram-
ming approach, Buecker et al. succeeded in establishing LIF-
responsive hES cell lines [82]. The authors claimed these cells
were more amenable to genetic manipulation than lines
maintained under standard hES culture conditions. Together,
these studies suggest the feasibility of generating naı ¨ve hES cells
and highlight their potential as a tool for genetic modification.
Future work will determine whether conditions can be established
that support the derivation and long-term propagation of naı ¨ve
hES cells direct from the human embryo.
Conclusions
Advances in our understanding of ES cell biology in the mouse
have led to the development of a culture condition for self-renewal
based on small molecule inhibitors of Fgf-MAPK signaling and
Gsk3. Employing these inhibitors, naı ¨ve pluripotent ES cells have
been derived from multiple strains of mouse and rat and are
presenting new opportunities for genetic intervention in these
species. It is plausible that since rodents have a capacity for
developmental suspension at the blastocyst stage, a phenomenon
known as diapause, that the ability to capture the naı ¨ve ES cell
state may be specific to the limited number of species with this
ability (discussed in [18]). However, until recently this cell type was
in practice a 129 mouse-specific phenomenon. Only by expanding
our knowledge of ES cell biology and developing defined
conditions have we succeeded in capturing and culturing ES cells
from multiple mouse strains, the rat, and through genetic
intervention, the human. These recent advances suggest that the
naı ¨ve pluripotent state may be conserved across species but that we
have lacked the means to capture it in vitro from hitherto
recalcitrant mammals. While this question primarily relates to
developmental stem cell biology, its resolution has consequences
for the study of genetics. We have already seen that the genomes of
genetically diverse mouse strains are easily accessed by 2i culture.
The unparalleled resource that naı ¨ve ES cells present for genetic
manipulation would be an invaluable tool if it could be readily
applied to a wider range of species. If we could manipulate the
genome of cultured human cells with the facility already achieved
in the mouse, this would represent a boon for developmental and
disease modeling in vitro. For many applications, including
livestock improvement or species conservation, developing a
widened array of ES or iPS cells from diverse species promises
new opportunities.
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